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College London, Queen Square, London WC1N 3BG, UKCytoplasmic dynein is the main retrograde motor in all
eukaryotic cells. This complex comprises different sub-
units assembled on a cytoplasmic dynein heavy chain 1
(DYNC1H1) dimer. Cytoplasmic dynein is particularly
important for neurons because it carries essential sig-
nals and organelles from distal sites to the cell body. In
the past decade, several mouse models have helped to
dissect the numerous functions of DYNC1H1. Addition-
ally, several DYNC1H1 mutations have recently been
found in human patients that give rise to a broad spec-
trum of developmental and midlife-onset disorders.
Here, we discuss the effects of mutations of mouse
and human DYNC1H1 and how these studies are giving
us new insight into the many critical roles DYNC1H1
plays in the nervous system.
Introduction
Cytoplasmic dynein 1 is a large (1.5 MDa), multisubunit
motor complex (Figure 1A) that moves towards the minus
end of microtubules in eukaryotic cells [1]. It belongs
together with the axonemal dyneins and cytoplasmic dy-
nein 2 to the dynein superfamily. Axonemal dyneins are
responsible for the movement of cilia and flagella, whereas
cytoplasmic dynein 2 has a role in intraflagellar transport
and is required for cilia and flagella assembly [1].
The core of the cytoplasmic dynein 1 complex is the
heavy chain (DYNC1H1) dimer (Figure 1A). Each heavy
chain is enormous – a half-megadalton protein – and,
perhaps unsurprisingly, serves multiple purposes. To-
wards the N terminal it has a long tail domain with binding
sites for other structural and regulatory components of the
dynein complex and docking sites for cargoes including0166-2236/$ – see front matter
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DYNC1H1 folds into a daisy-like structure comprising six
ATPase domains associated with diverse cellular activities
(AAA+) and a microtubule-interacting stalk region [2,3]
(Figure 1A,B). Thismotor domain drives the entire complex
and its cargoes along microtubules [2,4], although it is not
completely understood how ATP hydrolysis is coupled to
force generation or even the total number of ATPmolecules
bound to DYNC1H1 at any given time [4–6].
DYNC1H1 is highly conserved and is an essential pro-
tein in higher eukaryotes because the dynein complex has
housekeeping functions in all cells, including orientation of
the mitotic spindle, nuclear positioning, Golgi mainte-
nance, and endosomal dynamics [7–9]. In the nervous
system, the complex takes on additional roles specific to
neurons; driven by the heavy-chain motor, it transports
cargoes within dendrites and is the sole motor supporting
retrograde transport in axons – carrying signalling com-
plexes that affect gene expression, development, and re-
generation, misfolded proteins, and organelles from the
synapse back to the cell body. Interestingly, the analysis of
motor function in axons revealed that motor proteins,
including cytoplasmic dynein, strictly rely for axonal trans-
port on the local synthesis of ATP by glycolytic enzymes,
which are bound to transported organelles [10,11], and not
on mitochondrial ATP.
In mammals, new insight into DYNC1H1 function came
from characterising a set of dynein heavy chain mouse
mutations. Nowmutations in humans are also being found.
Both mouse and human data show that the dynein heavy
chain is essential for normal function of the nervous system
and even single conservative amino acid substitutions in
this > 500-kDa protein can result in neurological abnor-
malities.
An allelic series of DYNC1H1 mutants for understanding
the role of cytoplasmic dynein in the nervous system
Mouse Dync1h1 mutant strains
A phenotype arising from a single point mutation gives a
snapshot of protein function. By working with multiple
mutations of one protein, an ‘allelic series’, we gain a muchTrends in Neurosciences, November 2013, Vol. 36, No. 11 641
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Figure 1. The cytoplasmic dynein complex. (A) Diagram of the cytoplasmic dynein motor complex including the heavy chain (HC) dimer and its associated subunits. A
model of the motor domain [5] built from yeast cytoplasmic dynein (PDB ID 4AKG) and the mouse microtubule-binding domain (MTBD) (PDB ID 3ERR) assembled by Dr A.P.
Carter has been overlapped with the schematic of the dynein HC in its apo or post-power stroke form [5,93,94]. Adapted, with permission, from The Company of Biologists
(J. Cell Sci. 126, 705–713; [4]). The electron micrograph of an isolated molecule of monomeric dynein from Chlamydomonas reinhardtii flagella in its pre-power stroke form
is shown for comparison on the right. Adapted with permission from Macmillan Publishers (Nature 421, 715–718; [93]). Conformational changes driven by ATP hydrolysis in
the motor domain, which alter the relative position of the stem and the tail/linker, are hypothesised to lead to the power stroke and progression on microtubules [5,94]. The
HCs (in dark violet) contain the six AAA ATPase domains (in red), the stalk region, which includes the MTBD (in dark yellow and yellow, respectively), the buttress (in
orange), and the linker region. HCs are associated with light intermediate chains (LICs) (in green), intermediate chains (ICs) (in cyan), and light chains (LCs) (in light yellow).
(B) Domain composition of the cytoplasmic dynein HC. In addition to the functional domains shown in (A), this scheme displays the homodimerisation region and linker (in
white). The positions on the dynein HC of the three mouse mutations (Loa, Legs at odd angles; Cra, Cramping 1; Swl, Sprawling; bottom) and the human mutations
discussed in this review (top) are indicated.
Review Trends in Neurosciences November 2013, Vol. 36, No. 11richer picture – particularly helpful when trying to dissect
the function of a large protein like the cytoplasmic dynein
heavy chain.
Although fly and worm laboratories have worked at
the molecular level with multiple mutant alleles of the
dynein heavy chain for many years, the first mammalianTable 1. Cytoplasmic dynein-interacting proteinsa
Protein Type of binding Site/subunit Refs
LIS1 Direct DYNC1H1 (AAA3/AAA4 junction)
DYNC1H1 (AAA4 arginine finger)
[83]
NudE Indirect Intermediate chain
Light chain – LC8
[84]
Dynactin Indirect Intermediate chain [85]
Snapin Indirect Intermediate chain [86,87]
Htt Indirect Intermediate chain [88]
HAP1 Indirect Dynactin [88]
BICD1
BICD2
Indirect
Indirect
Dynactin
Intermediate chain
[89,90]
[91]
aThe table shows some of the interactors with the cytoplasmic dynein motor
complex involved in CNS development and homeostasis.
642DYNC1H1 mutation came in 1998 with a knockout mouse
(Table 2) [12]. In mouse and human, DYNC1H1 appears to
be a single isoform encoded by 78 exons [13]. Heterozygous
knockoutmice had no reported phenotype, but homozygous
nulls died early in gestation (<8.5 days) with Golgi appa-
ratus, endosome, and lysosome abnormalities, underlining
that DYNC1H1 is an essential protein with housekeeping
roles.
Insight into the nervous system function of Dync1h1
came with three further mutants: Legs at odd angles
(Dync1h1Loa), Cramping 1 (Dync1h1Cra1), and Sprawling
(Dync1h1Swl) mice [14,15] (Table 2 and Figure 1B).
Dync1h1Loa mice present a single point mutation from a
phenylalanine to a tyrosine (F580Y) in the dynein tail
domain. Surprisingly, the addition of a single hydroxyl
group onto the 532-kDa protein is enough to give rise to
a dominant phenotype [15]. This residue lies within the
binding site for dynein intermediate chains (ICs) [16]
(Figure 1B) and the homodimerisation region [16,17].
Dync1h1Cra1 mice have instead a single point mutation
at the opposite end of the homodimerisation domain
Box 1. Dync1h1Loa, Dync1h1Cra1, and Dync1h1Swl mutations and the Harwell connection
In 1994, one of the authors was talking to a member of Professor J.
Peters’ Laboratory of the MRC Mammalian Genetics Unit in Harwell,
UK, a world centre for mouse genetics since 1946. The Peters
laboratory produced novel mouse mutants with the chemical mutagen
N-ethyl-N-nitrosourea (ENU), which typically causes point mutations,
particularly A-to-T changes [95]. A discussion arose about a new
mutation that had disrupted locomotion. The first mouse described
was an obligate heterozygote female born in 1984 from a C3H/HeH
male previously treated with ENU and crossed to a PTP-strain female.
This ‘Legs at odd angles’ (Loa) mouse was noticed because of her
unusual locomotion and named because she held her legs at a strange
angle (limb grasping, a generic sign of neuromuscular/motor system
deficits) when rapidly suspended by the tail. This mouse and her
progeny were crossed to several inbred strains, but mainly the 101
strain. During the following behavioural characterisation [96], it was
noticed that heterozygous animals, which otherwise lived to a normal
age compared with wild type littermates, developed a slowly
progressive locomotor deficit that manifested as a low-based
‘reptilian’ gait and Rotarod test and grip-strength defects.
In that pre-genome project era, positional cloning of an unknown
mutant gene was a gruelling undertaking of several years. Having
found linkage of the Loa trait to mouse chromosome 12, the physical
maps spanning the critical region were published [97]. In 2001, the
critical region was displayed at the 15th International Mouse Genome
Conference, Edinburgh, UK. Dr Andreas Russ, then working for the
German Biotech company Ingenium saw the map and realised that
the description of the mutant and the position of the unknown
mutation were almost identical to that of a mouse mutation,
Cramping 1, created by the German ENU project [98]. The groups in
the UK and Germany cooperated and in 2003 found that the Loa and
Cra1 strains have point mutations in Dync1h1. The Loa mutation is a
transversion resulting in a change from phenylalanine to tyrosine at
position 580 (F580Y), whereas the Cra1 mutation changes tyrosine to
cysteine at position 1055 (Y1055C) [15]. The non-complementation
found in the compound heterozygotes (Dync1h1Loa/Cra) added con-
siderable weight of evidence that the correct mutations had been
identified.
The first Sprawling mouse, described in 1967, had been produced
from an irradiation experiment [18,19]. However, the causative
mutation was published only in 2007 by Popko and colleagues, who
determined that the phenotype arose from a 9-bp deletion in exon 12
of Dync1h1 that changed four amino acids (GIVT) to a single alanine
(A) residue in a cargo-binding domain [14]. The Sprawling mouse
strain originated at MRC Harwell.
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overlapping that of Dync1h1Loa [15–17] (Table 2).
Dync1h1Loa and Dync1h1Cra1 were generated by indepen-
dent chemical mutagenesis experiments (Box 1); a radia-
tion-induced mutant, Dync1h1Swl, has a small deletion
(G1040–T1043delinsA) in the proximity of theDync1h1Cra1
mutation (Table 2 and Figure 1B) and also produces a
dominant phenotype that primarily affects the nervous
system [14,18,19].
HomozygousDync1h1Loa andDync1h1Cra1mice die by 1
day after birth. This could potentially be due to a large
reduction in spinal cord motor neurons, limiting their
ability to feed [15]. By contrast, Dync1h1Swl homozygotes
die at the late implantation–early gastrulation stage
[14,18,19].
Human DYNC1H1 mutations
In 2010, the first human DYNC1H1 mutation
(DYNC1H1H3822P; Figure 1B and Table 3) was found in
an individual with developmental delay, hypotonia, and
brain malformations [20]. These phenotypic manifestations
are of great interest because cytoplasmic dynein isTable 2. Mouse mutations in the cytoplasmic dynein heavy chain
Approved allele name Allele Pheno
Mouse Dync1h1tm1Noh Knockout, created by gene targeting of
the first exon.
Hetero
with G
Mouse Dync1h1Loa Point mutation resulting in missense
change F580Y in homodimerisation
and dynein intermediate chain-binding
site; created by chemical mutagenesis.
Motor
neuro
reduce
birth.
Mouse Dync1h1Swl 9-bp deletion resulting in loss of three
amino acids from 1040–1043 (GIVT to
A); created by radiation mutagenesis.
Senso
spindl
Homo
Mouse Dync1h1Cra1 Point mutation resulting in missense
change Y1055C in homodimerisation
domain, created by chemical
mutagenesis.
Motor
neuro
Hetero
muscl
glucos
Homoessential for neuronal migration. A second mutation
(DYNC1H1E1518K) has also been found to cause severe
intellectual disability and other features [20,21]. Recently,
Poirer and colleagues reported seven novel de novo muta-
tions (two of them overlapping) and a small deletion, in
addition to a familial mutation, in individuals with mal-
formations of cortical development (MCD)22. MCD is char-
acterised by alterations of the cerebral cortex and is often
associatedwithsevere intellectual disability.Themutations
causingMCDare located indifferent domains ofDYNC1H1,
but several of them (DYNC1H1K3241T, DYNC1H1K3336N,
DYNC1H1R3344Q, DYNC1H1R3384Q) cluster in the stalk re-
gion and on the surface of its microtubule-binding domain
(MTBD) (Figure 1B) and have been shown to weaken bind-
ing of the dynein complex tomicrotubules [22]. The remain-
ing mutations lie in the first AAA ATPase domain (AAA1)
(DYNC1H1R1962C), in an area proximal to the linker region
(DYNC1H1R1567Q) and at the N terminus (DYNC1H1K129I)
of the tail domain, whereas the deletion (DYNC1H1D659-662)
was found within the binding sites for ICs and Light Inter-
mediate Chains (LICs) [16] (Figure 1B and Table 3). Al-
though the N terminus of the tail domain is not involved ingene
type of heterozygotes Refs
zygotes reported normal. Nulls die by embryonic day (E)8.5
olgi and other abnormalities.
[12]
, sensory, and other abnormalities. Loss of 50% motor
ns in E18.5 embryos. By 13 weeks, muscle spindles are
d by 86% in hind limbs. Homozygotes dead by 1 day after
[14,15]
ry early-onset neuropathy, with reduction of 88% of muscle
es in hind-limb muscles compared with wild type.
zygotes die in utero before E8.5.
[14,19]
, sensory, and other abnormalities. Loss of 20% of motor
ns in E18.5 embryos.
zygotes display progressive mitochondrial dysfunction in
e, hyperinsulinemia, and hyperglycaemia, progressing to
e intolerance with age.
zygotes dead by 1 day after birth.
[15,58]
643
Table 3. Human mutations in the cytoplasmic dynein heavy chain gene
Approved allele name Allele Phenotype of heterozygotes Refs
Human DYNC1H1K129I De novo point mutation resulting in missense
change K129I at the N terminus of the tail
domain.
Normocephaly. Pathological thick convolutions of the
posterior cerebral cortex (posterior pachygyria) and severe
intellectual disability. Late-onset epilepsy.
[22]
Human DYNC1H1H306R Point mutation resulting in missense change
H306R in homodimerisation domain.
Early-onset, slowly progressive distal lower-limb
weakness and wasting (similar to CMT2 neuropathy) or
SMA with lower-extremity predominance. Learning
difficulties in some individuals.
[24,25]
Human DYNC1H1I584L Point mutation resulting in missense change
I584L in homodimerisation and dynein
intermediate chain-binding site.
SMA with lower-extremity predominance. Normal upper-
extremity strength.
[26,33]
Human DYNC1H1D659-662 De novo 12-bp deletion resulting in loss of four
amino acids from 659–662 in
homodimerisation and dynein intermediate
chain-binding site.
Microcephaly associated with posterior pachygyria. Early-
onset epilepsy and spastic tetraplegia.
[22]
Human DYNC1H1K671E Point mutation resulting in missense change
K671E in homodimerisation and dynein
intermediate chain-binding site.
Early-onset, slowly progressive distal lower-limb
weakness and wasting. May have a ‘waddling’ gait. No
known sensory involvement.
[26]
Human DYNC1H1Y970C Point mutation resulting in missense change
Y970C in homodimerisation domain.
Significant motor delay, no known sensory involvement,
mild cognitive impairment.
[26]
Human DYNC1H1E1518K De novo point mutation resulting in missense
change E1518K.
Severe mental retardation, unable to walk or talk,
hypertonia and club feet; untested reflexes. Epilepsy.
Cortical malformation. Lack of sensory data.
[20,21]
Human DYNC1H1R1567Q De novo point mutation resulting in missense
change R1567Q.
Normocephaly. Excessive number of small convolutions
of the frontal cortex (frontal polymicrogyria) and severe
intellectual disability. Foot deformities.
[22]
Human DYNC1H1R1962C De novo point mutation resulting in missense
change R1962C in AAA1.
Normocephaly. Posterior pachygyria with severe
intellectual disability and awkwardness. Transient focal
epilepsy at early age.
[22]
Human DYNC1H1K3241T Familial point mutation resulting in missense
change K3241T in the stalk domain.
Normocephaly. Posterior pachygyria with mild or absent
intellectual disability and variable awkwardness. Focal
epilepsy.
[22]
Human DYNC1H1K3336N De novo point mutation resulting in missense
change K3336N in the stalk domain
(microtubule-binding domain [MTBD]).
Microcephaly associated with posterior pachygyria,
frontal polymicrogyria, and other CNS malformations.
Early-onset epilepsy. Spastic tetraplegia with foot
deformities.
[22]
Human DYNC1H1R3344Q Point mutation resulting in missense change
R3344Q in the stalk domain (MTBD). This de
novo mutation was reported in two unrelated
individuals.
Mild microcephaly associated with posterior pachygyria
with moderate intellectual disability and awkwardness.
Focal epilepsy.
[22]
Human DYNC1H1R3384Q De novo point mutation resulting in missense
change R3384Q in the stalk domain (MTBD).
Microcephaly associated with posterior pachygyria,
frontal polymicrogyria and other CNS malformations.
Early-onset epilepsy. Spastic tetraplegia with foot
deformities.
[22]
Human DYNC1H1H3822P De novo point mutation resulting in missense
change H3822P in a linker region between
AAA5 and AAA6 within the motor domain.
Hypotonia, moderately severe mental retardation, broad-
based, waddling gait, reduced reflexes. Bilateral deficient
gyration of the frontal lobes. Lack of sensory data.
[20,21]
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tory components, the dramatic effect of the DYNC1H1K129I
mutation (Table 3), together with mutagenesis analyses in
Aspergillus [23], suggest that this region of DYNC1H1 is
critical for cytoplasmic dynein functions in vivo, possibly for
the coordination of force production and movement under
heavy load [23].
DYNC1H1 mutations have also now been reported in
motor neuropathies, which may be accompanied by cogni-
tive impairment. The first such family presented with the
dominant hereditary distal motor neuropathy Charcot–
Marie–Tooth (CMT) type 2, with delayed motor milestones
and/or abnormal gait. Affected individuals have early-onset
lower-limb weakness and wasting caused by a mutation,
DYNC1H1H306R, within the homodimerisation domain of
the dynein heavy chain [24] (Figure 1B and Table 3). How-
ever, an independent family with an identical mutation644manifests symptoms of spinal muscular atrophy (SMA)
[25]. OtherDYNC1H1mutations have been found by exome
sequencing in families with a similar SMA presentation
[26]. The key clinical features in individuals with three
different mutations in the tail domain (DYNC1H1I584L,
DYNC1H1K671E, DYNC1H1Y970C) were congenital or very
early-onset weakness in the proximal legs and other areas
and a static or mildly progressive disease course. Clinical
findings support a diagnosis of motor neuron disease with-
out sensory involvement [26,27]. Interestingly,
DYNC1H1K671Eand theDYNC1H1D659-662deletion are only
10 residues apart, yet their main clinical outcome, MCD
associated with spastic tetraplegia, and motor neuron dis-
ease, respectively, are dramatically different.
The human and mouse mutations described so far are
all autosomal-dominant disorders with high penetrance; it
is unknown whether the phenotypes arise from gain of
Review Trends in Neurosciences November 2013, Vol. 36, No. 11function or hemizygous loss of function or, perhaps more
likely in such a large protein, a combination of both. There
is, however, evidence that theDync1h1Loamutation results
in reduced affinity between cytoplasmic dynein and the
p150 subunit of dynactin (DCTN1), a binding partner of
dynein (Table 1) [28] and in impaired motor processivity
[28,29], although it is unclear whether this is the sole cause
of the phenotype.
Consequences of DYNC1H1 mutations in the nervous
system
Locomotor and motor system deficits
Dync1h1Loa, Cra1, Swl heterozygous mouse mutants have
gait deficits that manifest by approximately 1month of age
(Table 2). They limb-clench when held by the tail and have
grip-strength deficits, which occur as early as 1 week after
birth in Dync1h1+/Swl mice [14,15]. Dync1h1+/Cra1 mice
have early-onset reduction in grip strength, which does not
progress [30] or mildly [31] progresses with age. Forelimb
strength and movement are preserved in Dync1h1+/Loa
mice [32].
Interestingly, all of the human DYNC1H1 mutation
cases have gait abnormalities ranging from spastic tetra-
plegia, inability to walk at all, and ‘waddling gait’ to mild
distal limb weakness; pes cavus or other foot deformities
are often a feature, indicating an underlying neuromuscu-
lar disorder [20,21,24–27,33] (Table 3). The striking simi-
larity between the locomotor phenotypes observed in
humans and mice suggest that DYNC1H1 plays crucial
roles in the physiological control of the motor system in
both species.
The first description of heterozygous Dync1h1+/Loa and
Dync1h1+/Cra1 mice reported a progressive loss of motor
neurons with a predominance of large type I fibres in
specific muscles [15]. However, later reports found no loss
of alpha motor neurons in Dync1h1+/Loa [14,34] or
Dync1h1+/Cra1 [30,35] mice. Although these contradictory
results are complicated by possible methodological differ-
ences (e.g., how different laboratories count large alpha
motor neurons), theymay also give insights for unravelling
the effect of genetic factors in dynein function, because one
possible source of variation is the genetic background of the
mice examined in different papers. Our original report [15]
described motor neuron loss in Dync1h1+/Loa mice with a
mixed genetic background that included at least C3H, PTP,
101, and C57BL/6, whereas subsequent studies were all on
congenic C57BL/6 [14,34]. It is therefore possible that
genetic background plays a modifying role on this pheno-
type.
This would not be the first case in which genetic back-
ground affects phenotype severity. In an establishedmouse
model of amyotrophic lateral sclerosis (ALS) (SOD1G93A),
the C57BL/6 background extends life comparedwith aC3H
background [36]. Extrapolating to theDync1h1mutants, it
is possible that alleles in the mixed genetic background
used in the original study enhanced motor neuron loss
whereas the C57BL/6 background was protective.
However, genetic effects are not an explanation of the
discrepancies found in Dync1h1+/Cra1 and Dync1h1+/Swl
mice [14,15,35], because these studies were performed
on mice of the same (C3H) or very similar (C3H/101)background. Curiously, neuromuscular junctions (NMJs)
have been found to be normal in Dync1h1+/Cra1 mice on a
congenic C3H background [35], whereas on amixed genetic
background that includes C3H, NMJs were reported as
abnormal [30].
As expected, embryos bearing homozygous mutations in
Dync1h1 (e.g., Dync1h1Loa/Loa and Dync1h1Cra1/Cra1) dis-
play augmented phenotypes with severe motor neuron
loss, although at present it is unknown whether these
are developmental or neurodegenerative defects.
How do these results help in deciphering the clinical
manifestations of human patients bearing mutations in
DYNC1H1? Motor neuropathy in human patients displays
different degrees of severity and includes distal wasting
and weakness with reduced or absent reflexes and chronic
distal denervation [27]. Distal motor neuron loss has
been suggested in DYNC1H1H306R, DYNC1H1I584L,
DYNC1H1K671E, and DYNC1H1Y970C patients [24–
26,33], whereas theDYNC1H1E1518K individual has hyper-
tonia and did not learn to walk [20,21]. Two interesting
observations arise from the human data that strengthen
the correspondence with the results obtained in the mouse
studies and may relate to the modifier effects of genetic
background found with the mouse mutations. First, the
human DYNC1H1I584L mutation lies almost on top of the
Dync1h1Loa mutation and is also very conservative (Ile to
Leu). The functional characterisation of this human muta-
tion indicates loss or dysfunction of motor neurons, akin to
the original observation in the Dync1h1+/Loa mice [15].
Henceforth, the Dync1h1+/Loa mouse may represent
an ideal system to model the pathophysiological effects
of the DYNC1H1I584L human mutation. Second,
DYNC1H1H306R manifests with distinct symptoms in dif-
ferent human pedigrees. In one (UK pedigree), patients
display a predominant axonal CMT2B disease [24], where-
as in the other (Japanese pedigree) they present with SMA
with lower extremity predominance [25], potentially dem-
onstrating the strong effects of genetic background also in
the human cases.
Sensory system defects
In addition to motor system deficits, mutations in the
dynein heavy chain also cause impairments in other areas
of the nervous systems, including sensory neurons. An
overt sensory phenotype is found in Dync1h1+/Swl mice,
which have early-onset sensory neuropathy probably due
to degeneration during late embryonic development
[14,18] (Table 2). These mice have proprioceptive and
nociceptive sensory neuron loss compared with wild types
[14]. Sensory nerve conduction velocities are reduced and
the mice have moderate sensory neuropathy arising from
the proprioceptive defect [14]. Similarly, Dync1h1+/Loa
mice have progressive loss of sensory axons from at least
1.5 months after birth, mostly from proprioceptive nerves
[34]. Branching and elongation of primarily sensory limb
nerves is impaired in E13.5 and E14.5 Dync1h1Loa homo-
zygotes and heterozygotes [15]. Dync1h1+/Cra1 mice have
milder loss of sensory axons than other Dync1h1 mutants
and, perhaps surprisingly, no difference in proprioceptive
neuron number ormorphology comparedwithwild types at
6 months of age [30].645
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of hind-limb clenching and low-based gait (Table 2). In
Dync1h1+/Loa and Dync1h1+/Swl, these features may be
due to proprioceptive defects. However, in Dync1h1+/Cra1
they may arise from dysfunction of the NMJ rather than
motor or sensory neurodegeneration, which fits with find-
ings from Drosophila and other model organisms in which
dynein disruption results in NMJ abnormalities [30].
This sensory phenotype is also found in human patients
withDYNC1H1mutations, but with important differences
that may be explained at least in part by modifier genes
associated with a different genetic background. Individua-
ls bearing theDYNC1H1H306Rmutation range from having
mild reduction of proprioception to deficits in all sensory
modalities in the UK pedigree [24], but normal sensory
nerve conduction and no obvious sensory abnormalities in
the Japanese pedigree [25]. Surprisingly, several human
patients with DYNC1H1 mutations have no obvious sen-
sory loss [22,26,33] (Table 3), raising the possibility that
this is due to a permissive genetic background in these
patients. An alternative explanation is that the human
sensory system is more robust than in rodents and is
protected from the deleterious effects of DYNC1H1 muta-
tion by compensatory mechanisms. In this regard, the
resulting sensory phenotype may be too subtle to be clini-
cally relevant and detected by current protocols.
Abnormalities in brain morphology and function
Dync1h1mutations affect brain function atmultiple levels.
Brain imaging showed striatal atrophy and lateral ventri-
cle enlargement in Dync1h1+/Cra1 mice, which also had
altered dopamine signalling. However, neuronal loss was
found only in the substantia nigra [31]. In humans, Perry
syndrome, an atypical Parkinson-like disease, can be
caused by point mutations in the p150 subunit of dynactin
[37] (Table 1). Furthermore, cytoplasmic dynein directly
binds huntingtin (Htt) and huntingtin-associated protein 1
(HAP1), two proteins involved in the physiology of the
dopaminergic system, via dynactin [38] (Table 1).
Correct cortical development also requires cytoplasmic
dynein. MCD has been detected in several cases with
DYNC1H1 mutations [21,22] and is often associated with
microcephaly, pachygyria (presence of pathological thick
convolutions of the cerebral cortex), polymicrogyria (exces-
sive number of small convolutions of the cortex), and other
central nervous system (CNS) malformations. Patients
often display early-onset or focal epilepsy and mild-to-
severe intellectual disability (Table 3). Interestingly, two
cases (DYNC1H1K3336N andDYNC1H1R3384Q) display both
pachygyria and polymicrogyria patterns, which are nor-
mally regarded as distinct clinical entities and have been
found associated only in patients with WDR62-related
brain abnormalities [39].
These malformations probably arise because the cyto-
plasmic dynein complex is important for neuronal migra-
tion [40]. This may also explain the abnormal migration of
facial motor neuron cell bodies to the hindbrain found in
E10.5 Dync1h1Loa/Loa embryos [15]. This striking pheno-
type was not observed for cranial and spinal nerves in the
neural tube, suggesting that the susceptibility of distinct
neuronal subtypes to the same Dync1h1 mutations varies646within the same genetic background. This possibility is
strengthened by the finding that alpha rather than gamma
trigeminal motor neurons or proprioceptive neurons are
affected in Dync1h1+/Loa mice, showing abnormal den-
drites, aberrant mitochondria, and other defects consistent
with altered trafficking of organelles [41]. Uncovering the
mechanistic basis of this differential sensitivity will great-
ly further our understanding of the factors determining
type-specific neuronal cell death as a response to generic
insults or mutations of ubiquitously expressed proteins, a
major unsolved problem in basic and clinical neuroscience.
Based on the importance of cytoplasmic dynein in mi-
crotubule-dependent movement [42], the effects of
Dync1h1mutations on axonal transport were tested.Motor
neuron cultures from Dync1h1Loa/Loa but not Dync1h1+/
Loa embryos show a highly significant reduction in axonal
retrograde transport [15,43]. The lack of an overt pheno-
type in heterozygous neurons is unexpected because mu-
tant DYNC1H1 acts as a dimer [15,28]. The DYNC1H1Loa
protein displays impaired run-lengths onmicrotubules [29]
and the human DYNC1H1I584L protein has decreased
binding to microtubules in the presence of ATP [26]. Both
mutations have a similar biochemical profile, which is
interesting given their proximity and highly conserved
nature. The lack of an axonal transport phenotype in
cultured Dync1h1+/Loa embryonic motor neurons was con-
firmed by assessing the retrograde transport of signalling
endosomes in the sciatic nerve of adult Dync1h1+/Loa mice
by intravital microscopy [44]. This technique allows the
quantitative real-time assessment of the retrograde move-
ment of transport organelles in the intact sciatic nerve of
living mice and revealed only a minor drop in high trans-
port speed in Dync1h1+/Loa mice (Figure 2), suggesting
that only a subset of the specific functions of dynein is
affected in these mice, causing a mild phenotype compati-
ble with life.
Mutations in dynein heavy chain and
neurodegenerative diseases
Although human DYNC1H1 mutations have been de-
scribed causing CMT2 neuropathy (DYNC1H1H306R)
[24], SMA (DYNC1H1H306R) [25], (DYNC1H1I584L, K671E,
Y970C) [26], and severe cognitive/neuronal migration defi-
cits (DYNC1H1E1518K, H3822P) [20,21], to date some of the
most interesting results for dissecting diseasemechanisms
come from the mouse mutants. In this section, we focus on
a subset of breeding experiments testing the genetic inter-
actions ofDync1h1mutations with known genes important
for neurodegenerative diseases.
ALS
ALS is a neurodegenerative disease that usually manifests
inmidlife and results in progressive loss of upper and lower
motor neurons, leading to paralysis and death within 3–5
years of diagnosis. Around 10–20% of ALS is an inherited
autosomal-dominant disease and of these familial cases,
about 10% are due to mutations in the superoxide dismu-
tase 1 (SOD1) gene. Mice carrying human mutant SOD1
transgenes model ALS [36,45] and develop deficits includ-
ing defective axonal retrograde transport (for example, see
[43,44,46]).
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Figure 2. Quantitative analysis of axonal retrograde transport by intravital microscopy. (A) Axonal retrograde transport of signalling endosomes containing a fluorescently
labelled atoxic fragment of tetanus neurotoxin was monitored in single axons in the intact sciatic nerve by time-lapse confocal microscopy and shown as a time series [44].
(B) The deficit in axonal retrograde transport observed in early symptomatic SOD1G93A transgenic mice (74  1.7 days; in red) is almost completely rescued by the
Dync1h1Loa allele in Dync1h1+/LoaSOD1G93A double-mutant mice (in blue). The speed distribution profile displayed by Dync1h1+/LoaSOD1G93A mice overlaps with that
observed in Dync1h1+/Loa animals (in green) and is slightly shifted towards lower speed values compared with wild type mice (in black) of similar age.
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Dync1h1+/Loa mice and double-mutant progeny (i.e.,
SOD1G93ADync1h1Loa) surprisingly lived 28% longer than
their SOD1G93A transgenic littermates, with a significant
increase in survival of spinal cord motor neurons at a 120-
day late-disease time point compared with SOD1G93A lit-
termates [43] (Table 4). Curiously, double mutants had an
increased rate of axonal retrograde transport in embryonic
motor neuron cultures compared with their single-mutant
and wild type littermates [43]. Interestingly, the Dyn-
c1h1Loa allele is able to rescue almost completely the
axonal transport deficits observed in early symptomatic
SOD1G93A mice, as shown by intravital microscopyTable 4. Genetic interactions between SOD1 and the cytoplasmic
Dync1h1 mutant mouse parent SOD1-ALS mutant mouse parent
Dync1h1+/Loa on C57BL/6
congenic background
SOD1G93A transgenic on hybrid SJL,
C57BL/6 background
Dync1h1+/Loa on C57BL/6
congenic background
SOD1G93A transgenic on hybrid SJL,
C57BL/6 background
Dync1h1+/Loa on C57BL/6
congenic background
SOD1G93A transgenic on C57BL/6
congenic background
Dync1h1+/Cra1 on C3H
background
SOD1G93A transgenic on congenic
C57BL/6 background
Dync1h1+/Swl on C3H/101
background
SOD1G93A transgenic on hybrid SJL,
C57BL/6 background
BICD2GFP-N on FVB
background
SOD1G93A low-copy transgenic on FVB/
N background
Dync1h1+/Loa on C57BL/6
congenic background
SOD1G37R transgenic on C57BL/6
congenic background
Dync1h1+/Loa on C57BL/6
congenic background
SOD1G85R transgenic on C57BL/6
congenic background
aEffects on lifespan (to humane end point) of double-mutant progeny from crossing SOD
in this review.(Figure 2). This restoration of axonal retrograde transport
may determine the amelioration of the ALS disease phe-
notype observed in Dync1h1LoaSOD1G93A double mutants,
including significant life extension (see below).
This phenomenonwas unexpected and therefore similar
experiments were performed by different laboratories by
crossing Dync1h1+/Loa mice to various mutant SOD1
strains. Although the increase in lifespan is reproducible
(21% life extension was found in an identical cross [14]),
changing the genetic background of SOD1G93A mice to
C57BL/6 reduced this increase to only 9% [34] (Table 4).
This effect was confirmed using a different Dync1h1 mu-
tation (Dync1h1+/Cra1). Indeed,,a 14% increase in time todynein complexa
Effect on lifespan of double mutants compared with SOD1-
ALS littermates (time to humane end point shown for SOD1-
ALS double mutants compared with their SOD1-ALS litter-
mates)
Refs
28% significant increase in lifespan (160 days, n = 18,
compared with 125 days, n = 20)
[43]
21% significant increase in lifespan (156 days, n = 12,
compared with 129 days, n = 16)
[14]
9% significant increase in lifespan (165 days, n = 9, compared
with 152 days, n = 9)
[34]
14% significant increase in lifespan (167 days, compared with
147 days, n = 14/15)
[47]
No significant differences in lifespan (124 days double
mutants, n = 15, compared with 122 days single mutants,
n = 15)
[14]
14% increase in lifespan (271 days, n = 12, versus 237 days,
n = 12
[48,92]
No significant differences in lifespan (192 days, n = 10,
compared with 189 days, n = 28)
[34]
6% increase in lifespan (386 days, n = 14, compared with 364
days, n = 43)
[34]
1-ALS mutant mice to animals with mutations inDync1h1or other strains discussed
647
Review Trends in Neurosciences November 2013, Vol. 36, No. 11humane end point was found in Dync1h1+/Cra1SOD1G93A
double mutants compared with SOD1G93A littermates [47].
Further support for a functional interaction betweenSOD1
and the dynein motor is provided by work using a trans-
genic mouse with chronically impaired cytoplasmic dynein
and dynactin function because of neuronal expression of
Bicaudal D2 N terminus (BICD2GFP-N) [48]. BICD2 is a
conserved motor-adaptor protein that is involved in dy-
nein-mediated transport by linking the dynein motor com-
plex to various cargoes (Table 1). It plays a major role in
organelle trafficking in various cells, including neurons,
and its mutation causes autosomal-dominant SMA and
hereditary spastic paraplegia (HSP) [49–51]. Double
mutants of BICD2GFP-N with ‘low-copy’ SOD1G93A mice
also show an increased lifespan (+14%), further supporting
a genetic interaction between SOD1 and cytoplasmic dy-
nein and suggesting that the expression level of the
SOD1G93A transgene is not likely to play a role in this
phenomenon.
What is the molecular mechanism at the basis of the
amelioration of the ALS phenotype byDync1h1mutations?
Expression of SOD1G93A in primary motor neurons alters
the cellular localisation of cytoplasmic dynein [52]. As a
consequence, SOD1G93A mice have axonal transport
defects and a change of cargoes in the axon from survival
signals to stress/death signals [53]. Thus, inhibiting a
specific subset of retrograde organelles may help delay
the activation of cell stress pathways. This could help
motor neurons to survive SOD1G93A toxicity [53] and
may determine the rescue of axonal retrograde transport
deficits observed in Dync1h1LoaSOD1G93A double mutants
by intravital microscopy (Figure 2). Additionally, differ-
ences in the expression of the main anterograde motor
kinesin 1 have also been noted in Dync1h1+/Cra1SOD1G93A
mice [54].
Although the presence of a direct interaction between
DYNC1H1 and SOD1 remains controversial [55,56], Dyn-
c1h1LoaSOD1G93A mice have significant reductions in mu-
tant SOD1 protein in the mitochondrial matrix [57] that
determine amelioration of mitochondrial respiration and
restoration of membrane potential in embryonic motor
neurons. Therefore, these neurons are more resistant to
the toxic effects ofmutant SOD1 onmitochondria [57]. This
phenotype is surprising given that mouse fibroblasts de-
rived from Dync1h1+/Cra1 and Dync1h1Cra/Cra1 embryos
display profound alterations of mitochondrial morphology
and that Dync1h1+/Cra1 mice develop, hyperinsulinemia,
hyperglycaemia, and progressive mitochondrial dysfunc-
tion [58]. Similar mitochondrial abnormalities have also
been reported in fibroblasts isolated from SMA patients
carrying the DYNC1H1I584L and DYNC1H1K671E muta-
tions [58].
Tau redistribution has also been called on to explain the
increased lifespan found in double-mutant animals.
Dync1h1+/Cra1SOD1G93A mice display some restoration
of tau isoform ratios compared with single-mutant ani-
mals, although the main effects were in the cortex and
cerebellum rather than the spinal cord [59]. Dync1h1Cra1-
SOD1G93Amice also show increased systemic expression of
insulin-like growth factor 1 (IGF-1), which may contribute
to the amelioration of the SOD1G93A disease phenotype648[60]. Indeed, viral delivery of IGF-1 to the CNS has been
shown to delay motor neuron death in SOD1G93A mice [61],
although the efficacy of IGF-1-based therapy in ALS
patients remains controversial [62]. An improved disease
outcome may also result from reduced excitotoxicity
caused by loss of glutamatergic proprioceptive sensory
neurons [34]. However, this seems unlikely because the
Dync1h1Swl mutation, which causes a greater loss of such
neurons, does not rescue the mutant SOD1G93A phenotype
[14] (see below).
Despite these intriguing results, no significant increase
in lifespan was observed when the Dync1h1+/Loa mouse
was crossed to two other SOD1-ALS models: dismutase-
active SOD1G37R and dismutase-inactive SOD1G85R trans-
genic mice [34]. Similarly, a comparable Dync1h1+/Swl
cross with SOD1G93A mice showed no effect of this dynein
mutation on lifespan [14] (Table 4). Despite active research
in this area, the molecular basis for these discrepancies is
presently unknown, although the slower progression, low-
er penetrance, and severity of the SOD1G37R and
SOD1G85R mutant phenotypes may explain some of the
experimental differences found using these strains.
Huntington’s disease (HT) and other neurological
diseases
Functional interactions with other genes implicated in
human neurodegenerative diseases, in addition to ALS,
have also been inferred. Treatment of cells expressing
mutant Htt or alpha-synuclein, which are mutated in
HD and Parkinson’s disease (PD), respectively, with a
cytoplasmic dynein inhibitor caused inhibition of the clear-
ance of both aggregate-prone proteins by autophagy [63].
When Dync1h1+/Loa mice were crossed to an HD model,
tremor onset and severity were greatly enhanced by the
dynein mutation in the double-mutant progeny, which had
significantly shorter lifespans [63]. This was thought to
arise from the deleterious effects of the Dync1h1Loa muta-
tion on autophagy, which relies on cytoplasmic dynein for
the intracellular transport and fusion of autophagosomes
with lysosomes [63]. Interestingly, Htt and HAP1 help to
control vesicle transport by interacting with the dynein–
dynactin complex [38] and mutant Htt adversely affects
dynein transport of brain-derived neurotrophic factor
(BDNF) [64,65]. Crucially, Htt protein levels are decreased
in dynein-mutantmice [64]. Interestingly, defects in brown
and white adipose tissues were found in Dync1h1+/Loa and
Dync1h1+/Cra1 mice, reminiscent of those seen in human
HD patients, potentially because of the functional role of
dynein in lipid droplet trafficking [66].
Enhancement of the severity of the disease phenotype
was also observed in other animal models of neurodegen-
eration crossed with Dync1h1+/Loa mice. Mutations in the
enzyme glycyl-tRNA synthetase (GARS) cause motor and
sensory axon loss in humans due to dose-dependent gain of
function and give rise to clinical phenotypes that range
from forms of CMT neuropathy to severe infantile SMA. A
mouse with a missense mutation in theGars gene that has
locomotor and sensory deficits was crossed toDync1h1+/Loa
mice and, as expected, the double mutants were more
severely affected than either parent [67]. However, it is
presently unclear whether this increase in severity is
Box 2. Outstanding questions
 How do mutations in Dync1h1 and DYNC1H1 generate such a
broad spectrum of phenotypes ranging from motor neuropathies
to malformations of the cerebral cortex?
 Why do these mutations have cell specificity?
 How many different types of cytoplasmic dynein complex exist in
a eukaryotic cell?
 How is the assembly of cytoplasmic dynein complexes of specific
composition regulated in different cell types?
 What is the basis of the functional interaction between SOD1 and
Dync1h1 in mice and humans?
 Why do the known Dync1h1 and DYNC1H1 mutations have
overlapping phenotypes but remain distinct from each other?
 Why do nearly overlapping mutations in Dync1h1 and DYNC1H1
give rise to dramatically different phenotypes and clinical out-
comes?
 What is the precise role of genetic background in the clinical
phenotypes of Dync1h1 and DYNC1H1 mutations?
 What are the roles of the novel domains identified by the
mutations recently found in DYNC1H1 in dynein function and
regulation?
Review Trends in Neurosciences November 2013, Vol. 36, No. 11linked to a defect in the known role of GARS in translation,
amino acid mischarging, or a still unknown mechanism
[68].
Several pathogens and virulence factors exploit cyto-
plasmic dynein and other molecular motors to reach their
site of action or replication, harness the biosynthetic ma-
chinery towards their replication compartment, or leave
their host and spread [69] to other cells or tissues. In
agreement with this view, vesicles containing mammalian
prion protein (PrPC) have been shown to engage both
cytoplasmic dynein and kinesin 1 for their intracellular
movement [70] and clinical prion disease correlates with
impaired axonal transport inmotor neurons [71]. However,
no differences in prion disease incubation timeswere found
in Dync1h1+/Loa and wild type littermates inoculated
intraperitoneally and intracerebrally with mouse-adapted
scrapie protein [72]. This result suggests that, although
PrPC undergoes dynein-mediated intracellular trafficking,
PrPSc toxicity relies on alternative transport mechanisms
independent of this molecular motor. This conclusion is in
agreement with recent evidence showing that the plasma
membrane is a primary site for prion conversion [73,74]
and that the transfer of PrPSc among adjacent cells could
occur via tunnelling nanotubes [75].
Concluding remarks and future perspectives
The cytoplasmic dynein heavy chain is involved in house-
keeping and neuron-specific cellular processes. The first
allelic series of Dync1h1 mutations in mice provided im-
portant insight into the function of this motor complex, but
at the same time highlighted some phenotyping differences
between investigating laboratories that remain incom-
pletely understood. Crucially, several mutations now
found in human DYNC1H1 are enriching the picture
and clearly show pivotal roles for this motor complex in
nervous system function. Disruption of DYNC1H1 results
in developmental and degenerative defects, which may be
modulated by genetic background. It is highly likely that
more human andmousemutations will be found, which will
provideuswithabetterunderstandingof the rolesplayedby
this very large protein. Many intriguing questions remain
(Box 2), such aswhy the knownmutations have overlapping
phenotypes but remain distinct from each other. This could
be partly explained by potential disruption of binding by
different cargoes and adaptors [42], for example, and we
note the strong correlation in phenotype between themouse
Dync1h1Loa and the human DYNC1H1I584L mutations.
Newly identified variants in regions of Dync1h1 that are
still poorly understood, such as the buttress, the linker
region, and the C-terminal end of the molecule
(Figure 1B), will provide us with novel information on
how these domains contribute to the force-generating pro-
cess and determine the step size of this molecular motor.
Similarly, we have only a partial understanding of the
coordination of the six AAA ATPase subunits. Novel muta-
tions in this region of DYNC1H1, such as the recently
discovered DYNC1H1R1962C in AAA1, will greatly help us
to dissect the precisemechanismofATPhydrolysis and how
chemical energy is translated into mechanical force.
With respect to neurodegeneration, defects in axonal
retrograde transport, which ismainly driven by cytoplasmicdynein, have been reported in several neurodegenerative
diseases [42,46,76] and cytoplasmic dynein trafficking is
involved in processes that are often aberrant, including
stress granule formation and trophic factor signalling.
The intriguing finding of extended lifespan in Dync1h1+/
LoaSOD1G93A double-mutantmicemay inspire newavenues
of research into novel potential drugs modulating axonal
retrograde transport rate. Sadly, even a 10% increase in
lifespan in humanswith ALSwould currently be a triumph.
Thus, the interplay of mutant SOD1 and DYNC1H1
deserves further investigation as well as the reason why
the lifespan-enhancing effect of Dync1h1+/Loa has been
found, to date, only with a specific human SOD1 mutation.
With respect to development, a recent study has shown
that DYNC1H1 is of fundamental importance for cell-size
sensing, especially in neurons, and indeed there are defects
in neuronal length in Dync1h1+/Loa mice [77]. The nature
of the signals transported by cytoplasmic dynein regulat-
ing cell size and the pathways responsible for this process
are presently unknown. However, their discovery holds
promises for the exploitation of this machinery to sustain
axonal regeneration and homeostasis in pathologies in
which axonal integrity is compromised, such as CMT2
and HSP [78].
We have confined this review to data obtained from
studies in mice and humans, but several results from other
model organisms also support the key role of cytoplasmic
dynein in neuronal physiology. These include studies in
Drosophila, where the creation of an allelic series of cyto-
plasmic dynein heavy-chain (cDhc64C) mutants provided
an early demonstration that disruption of cDhc64C (and
the dynactin orthologue p150Glued) causes bidirectional
disruption of axonal transport [79], thus suggesting that
retrograde and anterograde transport are tightly coordi-
nated. More recently, the zebrafish dync1h1 cannonball
mutant has disrupted photoreceptor morphogenesis, re-
vealing multiple roles for the protein in retinal develop-
ment [80]. Importantly, the general principles learned by
studying cytoplasmic dynein in metazoans can be trans-
ferred to lower organisms. The Dync1h1Loa mutation has649
Review Trends in Neurosciences November 2013, Vol. 36, No. 11been recreated in Neurospora, allowing further dissection
of the molecular effects including alterations in dynein
localisation and impaired speed of vesicle transport [81].
Future studies using protocols allowing the reconstitution
of human cytoplasmic dynein from recombinant subunits
[82] will allow the in vitro assembly of cytoplasmic dynein
complexes containing specific heavy-chain mutants, such
as those described in mouse and human animal models.
These mutant complexes may then be tested in in vitro
motility assays, allowing us to uncover the secrets of this
fascinating molecular motor and its complex network of
interacting proteins and regulators. Integration of in vitro
studies addressing how cytoplasmic dynein works at the
molecular level with future genetic investigations in mice
and humans will be key to understanding how cytoplasmic
dynein juggles such a range of functions and its so many
physiological masters.
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